Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes.
about
Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetesDifferential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis.Effects of 6-month sitagliptin treatment on glucose and lipid metabolism, blood pressure, body weight and renal function in type 2 diabetic patients: a chart-based analysis.Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.Renal Function During an Open-Label Prospective Observational Trial of Sitagliptin in Patients With Diabetes: A Sub-Analysis of the JAMP Study.
P2860
Q30240823-AF65DA9E-5683-433A-9B1B-B041ADC2D3AEQ33607755-EC59EE7F-8369-4723-BBDD-7B1878DCF25BQ36124544-4F7AF33D-DC5E-4DBE-AF39-FE04EFB0C011Q36132211-00E699C7-6021-4096-BB3C-8F0F3D7B0857Q38076330-3C166847-074F-4229-A2F8-0570F1E90751Q38177173-4A54D51E-3B6F-4892-8C02-8B66EED84DDCQ38527885-30665A00-B2A4-4E91-AE5C-D743D28CC0B8Q38716033-1C298B21-AD5A-4165-9F90-EE048DDEF289Q38795046-E93CD241-2387-46A5-BE49-54C39C3F29D7Q41259354-AF3DC33E-0BDA-4478-A3C1-967803073730Q43853440-3AA65304-1842-411C-8C8F-BBB612EA0F93Q47140737-A44446AC-CB35-4AF2-AD09-11D30844EDEF
P2860
Sitagliptin added to treatment with ongoing pioglitazone for up to 52 weeks improves glycemic control in Japanese patients with type 2 diabetes.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Sitagliptin added to treatment ...... patients with type 2 diabetes.
@ast
Sitagliptin added to treatment ...... patients with type 2 diabetes.
@en
type
label
Sitagliptin added to treatment ...... patients with type 2 diabetes.
@ast
Sitagliptin added to treatment ...... patients with type 2 diabetes.
@en
prefLabel
Sitagliptin added to treatment ...... patients with type 2 diabetes.
@ast
Sitagliptin added to treatment ...... patients with type 2 diabetes.
@en
P2093
P2860
P1476
Sitagliptin added to treatment ...... patients with type 2 diabetes.
@en
P2093
Atsunori Kashiwagi
John M Amatruda
Juan Camilo Arjona Ferreira
Kenji Nonaka
Mikio Nishii
Naoko Tajima
Tadaaki Taniguchi
Takashi Kadowaki
P2860
P304
P356
10.1111/J.2040-1124.2011.00120.X
P577
2011-10-01T00:00:00Z